Stock Monitor: BioLife Solutions Post Earnings Reporting
LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want access to our free research report on Milestone Scientific, Inc. (NYSE: MLSS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MLSS as the Company's latest news hit the wire. On May 14, 2018, the Company announced that it has inked an agreement with a leading Midwestern distributor and other distributors to promote the sale of CompuFlo® Epidural System in the United States. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for BioLife Solutions, Inc. (NASDAQ: BLFS), which also belongs to the Healthcare sector as the Company Milestone Scientific. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Milestone Scientific most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Milestone Scientific Decided to Pursue a Decentralized Sales Strategy Employing Regional Distributors
Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, stated that after careful evaluation of various options, the Company decided to pursue a decentralized sales strategy employing regional distributors with strong physician relationships within their respective territories and clinical specialties. According to Leonard, Milestone Scientific is targeting distributors with highly specialized sales forces that have the ability to both educate and inform anesthesiologists on the clinical benefits of the CompuFlo® Epidural System.
Leonard added that at the same time, the Company has entered into the first such agreement with a leading distributor that brings very strong relationships with key opinion leaders and anesthesia providers across key markets in the Midwest. Milestone Scientific is now in discussions with other distributors nationwide and looks forward to announcing similar agreements in the coming weeks and months as it develops its sales channels in advance of having the results of the clinical trials published in select industry journals later this year.
Milestone Scientific Received 510(k) FDA Clearance for CompuFlo® Epidural Instrument
In June 2017, the CompuFlo® Epidural Computer Controlled Anesthesia System received 510(k) clearance from the US Food and Drug Administration (FDA). Clearance from the FDA is considered globally to be the regulatory gold standard in premarket review. The clearance was supported by the COMPASS Study (CompuFlo® Assessment Study), which was a prospective, randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of epidural space verification with the CompuFlo® Epidural Instrument. The overall results of the COMPASS study demonstrated that the CompuFlo® Epidural could serve as an everyday epidural needle placement confirmation solution.
About CompuFlo® Epidural System
The CompuFlo Epidural's pressure sensing technology provides an objective tool for medical professionals to consistently and accurately identify the epidural space. Knowing the precise location of a needle during an epidural injection procedure provides a measure of safety not presently available to doctors using conventional syringes, who rely on their subjective perception to identify the epidural space. The CompuFlo® Epidural incorporates Milestone Scientific's patented DPS Dynamic Pressure Sensing Technology®. It differentiates tissue types for the medical professional via visual and audio feedback, leading to precise location guidance as the needle advances toward the intended area.
About Milestone Scientific, Inc.
Founded in 1989 and headquartered in Livingston, New Jersey, Milestone Scientific is a biomedical technology research and development company that patents, designs, develops, and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic, and veterinary applications.
Stock Performance Snapshot
May 15, 2018 - At Tuesday's closing bell, Milestone Scientific's stock ended the trading session flat at $0.69.
Volume traded for the day: 16.67 thousand shares.
After yesterday's close, Milestone Scientific's market cap was at $22.25 million.
The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.